NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » C&O Pharmaceutical Technology (Holdings) Limit back to previous page show list

C&O Pharmaceutical Technology (Holdings) Limit

address: Principal office in Hong Kong:
Room 1601-03, 16/F., West Tower,
Shun Tak Centre,
No. 168-200 Connaught Road Central,
Hong Kong
contact: Telephone Number:
+852 2806 0109.

Fax Number:
+852 2887 8445.

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: YES
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 
Corporate Profile
The Group is an established and integrated pharmaceutical group in the PRC.

They are growth oriented with the vision to be one of the leading pharmaceutical enterprises in China. In addition to steady organic growth, the Group is actively working with overseas pharmaceutical companies to expand our business and we are also able to leverage on its financial strengths to acquire complementary pharmaceutical businesses for expansion.

Their principal activities include the research, manufacturing and marketing of C&O branded pharmaceutical products as well as the distribution of third party pharmaceutical products in all parts of China. They also research, develop and sell technical know-how relating to pharmaceutical products and provide contract research organization (CRO) services.

Its manufacturing facilities are located in Nanjing, the PRC.
Pharmtech and R&D : Nanjing,Shenzhen,Shanghai
 
 
Service:

(1) Marketing and selling third-party pharmaceutical products in the PRC

(2)
Manufacturing, marketing and selling our own pharmaceutical products (including, in particular, medicinal products) in the PRC

(3)
R&D, provision of CRO services and selling of technical know-how relating to pharmaceutical products

Board of Directors
GAO Bin is the Executive Chairman of our Board appointed on 2 September 2003 and one of the founders of our Group. He is responsible for the overall strategic planning and business development of our Group. Mr Gao graduated from Nanjing Technical Training Institute in 1979 and obtained the professional qualification of senior economist in 1999. He has over 23 years’ experience in sales and marketing of pharmaceutical products in the PRC, from which he has created a vast network in the pharmaceutical sector and has gained a good knowledge of the development in the industry. From November 1981 to December 1992, Mr Gao was employed by Jinling Pharmaceutical Co., Ltd. (“Jinling Pharmaceutical”) in which he started as a sales executive, and the last position held was an associate director in charge of sales and distribution. During his employment with Jinling Pharmaceutical, he was in charge of the launch of a new product, Mai Le Ning, a Chinese medicine for injections for the treatment of angiitis, which became one of the best selling products of Jinling Pharmaceutical.

From January 1993 to April 2001, Mr Gao joined Nanjing Yangtze Development Corporation Co., Ltd. ("Yangtze") in the PRC as a manager in charge of its pharmaceutical business. Yangtze was appointed by Bright Future Pharmaceutical Laboratories Limited ("Bright Future") as its exclusive distributor in the PRC with effect from 1993. In 1994, Mr Gao was in charge of the launch of Amoxycillin, an orally-ingested amoxicillin in the PRC market and was instrumental in the development of Amoxycillin into a premium product in the PRC market. Mr Gao is responsible for, among others, overseeing all marketing activities and monitoring of distribution channels in relation to Bright Future Products as well as our own products.

Apart from that, Mr Gao was instrumental in publicising the brand name of Okin, an obesity drug, which has become one of the top brands for similar products in the PRC.


MA Lai Chi

Executive Director

MA Lai Chi is an Executive Director appointed to our Board on 2 September 2003 and one of the founders of our Group. Mr Ma is responsible for overseeing the administration functions of our Group. He graduated from Xiamen Diyi High School in 1966 and has over 22 years’ experience in international trading of pharmaceutical products. Prior to founding our Group, Mr Ma worked for Singee International Company Limited, Alpha Chemicals Limited and Prosperous Star Pharmaceutical Ltd. He subsequently managed his own trading companies under the company names of Golden Horse Chemicals Limited and MAS International (HK) Company Limited. Both companies had ceased business.


SONG Ming

Executive Director

SONG Ming is an Executive Director appointed to our Board on 12 August 2005 and also the chairman of Nanjing Chang Ao Pharmaceutical Co., Limited. He is responsible for overseeing our PRC operations. Mr Song obtained a bachelor’s degree in chemical engineering from Sichuan University in 1982 and a bachelor’s degree in law from Nanjing University in 1989. Prior to joining our Group in 1997, Mr Song was a teaching staff at China Pharmaceutical University for more than 11 years and the general manager of CPU Pharmaceutical Co., Ltd.

Mr Song received the Star entrepreneur award from the Education Committee of Jiangsu Province, and an award for Outstanding Factory Manager in Nanjing City from the Economic Committee of Nanjing City, Economic Reform Committee of Nanjing City, Labour Union of Nanjing City and Enterprise Management Committee of Nanjing City in 1996. He obtained the professional qualification of senior engineer in chemical engineering in 1999.


WU Su Min

Executive Director

WU Su Min is an Executive Director appointed to our Board on 12 August 2005 and also the general manager of Nanjing Chang Ao Pharmaceutical Co., Limited. He is responsible for overseeing the production of our Group. He obtained a bachelor’s degree and a master’s degree in pharmacology from China Pharmaceutical University in 1987 and 1997 respectively. Mr Wu has more than 17 years’ experience in the production of pharmaceutical products. Prior to joining our Group in 1999, Mr Wu was employed by CPU Pharmaceutical Co., Ltd. Mr Wu obtained the professional qualification of senior engineer in chemical engineering in 1999.

GAO Bin
Executive Chairman

LiZhan
Executive Director
Zhan is an Executive Director and also the general manager of Nanjing Changao Pharmaceutical Science &Technology Co.,Ltd.He is responsible for overseeing the research and development of new pharmaceutical products .Mr Li obtained his bachelor's degree in pharmacology from China Pharmaceutical University in 1994 and a master’s degree in business administration from Asia International Open University in Macao in 2000. He was awarded second prize for scientific and technological advancement by the Nanjing Municipal People’s Government, Jiangsu Province, the PRC in 2001 and the title of "Young and Middle-aged Forerunner in Industrial Technologies of Nanjing Municipality" in March 2006.

He has over 10 years’ experience in the research and development of pharmaceutical products to treat diseases of the kidney and liver. Prior to joining our Group in August 2001, Mr Li was an instructor at China Pharmaceutical University and employed by Jiangsu Changao Pharmaceutical Company Limited as a technical manager where he was responsible for research on new pharmaceutical products and development of pharmacology.

During his employment at China Pharmaceutical University from 1994 to 1996, he taught pharmacology and undertook research and development projects and published articles in respect of his studies relating to diseases of the kidney and liver in the China Pharmaceutical University publications.
 
Competitive Strengths
(1) Strong Management Team

They have a strong management team with extensive industry experience. Gao Bin, the Executive Chairman and Controlling Shareholder of the Company, has over 20 years of experience in the pharmaceutical industry in the PRC. He has built up a strong and effective management team for our Group. Half of the senior management team of the Group has more than 20 years of experience in the pharmaceutical industry in the PRC.

(2) Effective Sales and Marketing Team and Extensive Distribution Network
They have an effective sales and marketing team of over 800 personnel and an extensive distribution network covering the whole of the PRC which enables us to distribute pharmaceutical products quickly and extensively to the retailers of pharmaceutical products and also avails  pharmaceutical products and other third party pharmaceutical products in all provinces, autonomous regions and directly administered municipalities in the PRC. A key element of marketing and distribution strategy is to identify potential markets in the PRC and sell pharmaceutical products, either as agent or principal, by focused promotion and marketing. Individual sales teams are responsible for coordinating our Group's marketing activities in their designated provinces. The sales teams are given considerable autonomy, which enables us to respond quickly and flexibly to sales and changes in the market environment in individual national market segments.

(3) Strong R&D Capabilities
They have strong R&D capabilities which allows to conduct substantial part of the R&D process in-house without having to outsource to third parties and to sell R&D results. Their strong R&D capabilities also avail them of an active pipeline of over 50 potential new products and provide a strong base for our C&O brand products. They currently have more than 55 researchers in their R&D department. They also currently have a panel of six consultants whose depth of knowledge and breadth of experience can assist R&D work.

(4) GMP-Certified Production Processes
their production processes are GMP-certified and have implemented a stringent quality management system to ensure that production processes are in accordance with stipulated standards and procedures.

(5) Inclusion and Listing of Drugs under National Medical Schemes
The Bright Future Products and more than 10 of our C&O branded products (e.g. Amoxycillin, Cefradine, Cefradine for Injections, Cefuroxime Sodium for Injections, Azithromycin Dihydrochloride for Injections, Clelin, Antaen, Firest, Somatostatin for Injections, Calcium Dobesilate Tablets, Amoxicillin and Clavunalate Potassium Chewable tablets, Vitamin U Aluminium Hydroxide and Magnesium Trisilicate Capsules and Domperidone Maleate tablets) are listed on the National Basic Medical Treatment Insurance and Medicine for Work Injury Insurance List issued by the Ministry of Labour and Social Security in the PRC, which may potentially result in better marketability, as the cost of drugs listed on the list is covered by national health insurance and people covered by health insurance will accordingly choose to buy medicines that are on that list.

(6) Recognition for Technological Innovation
products have received positive recognition in the market for technological innovation.
 
Future Plans


(1) Expand distribution network

(2) Increase production capacity

(3) Expand product range and enhance R&D capabilities

(4) Strengthen market recognition of  Group and C&O branded products through promotions and advertisements

(5) Collaboration with business partners within the PRC and overseas

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.